共 50 条
A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration
被引:27
|作者:
Sime, Fekade B.
[1
,2
]
Lassig-Smith, Melissa
[3
]
Starr, Therese
[3
]
Stuart, Janine
[3
]
Pandey, Saurabh
[1
]
Parker, Suzanne L.
[1
]
Wallis, Steven C.
[1
]
Lipman, Jeffrey
[1
,3
,4
]
Roberts, Jason A.
[1
,2
,3
,4
,5
]
机构:
[1] Univ Queensland, Ctr Clin Res, Fac Med, Brisbane, Qld, Australia
[2] Univ Queensland, Ctr Translat Antiinfect Pharmacodynam, Sch Pharm, Brisbane, Qld, Australia
[3] Royal Brisbane & Womens Hosp, Dept Intens Care Med, Brisbane, Qld, Australia
[4] Univ Montpellier, Nimes Univ Hosp, Div Anaesthesiol Crit Care Emergency & Pain Med, Nimes, France
[5] Royal Brisbane & Womens Hosp, Pharm Dept, Brisbane, Qld, Australia
基金:
英国医学研究理事会;
关键词:
ceftolozane-tazobactam;
pharmacokinetics;
renal replacement therapy;
hemodiafiltration;
CRRT;
RENAL REPLACEMENT THERAPY;
PSEUDOMONAS-AERUGINOSA;
CLEARANCE;
D O I:
10.1128/AAC.01655-19
中图分类号:
Q93 [微生物学];
学科分类号:
071005 ;
100705 ;
摘要:
The aim of this work was to describe optimized dosing regimens of ceftolozane-tazobactam for critically ill patients receiving continuous venovenous hemodiafiltration (CVVHDF). We conducted a prospective observational pharmacokinetic study in adult critically ill patients with clinical indications for ceftolozane-tazobactam and CVVHDF. Unbound drug concentrations were measured from serial prefilter blood, postfilter blood, and ultrafiltrate samples by a chromatographic assay. Population pharmacokinetic modeling and dosing simulations were performed using Pmetrics. A four-compartment pharmacokinetic model adequately described the data from six patients. The mean (+/- standard deviation [SD]) extraction ratios for ceftolozane and tazobactam were 0.76 +/- 0.08 and 0.73 +/- 0.1, respectively. The mean +/- SD sieving coefficients were 0.94 +/- 0.24 and 1.08 +/- 0.30, respectively. Model-estimated CVVHDF clearance rates were 2.7 +/- 0.8 and 3.0 +/- 0.6 liters/h, respectively. Residual non-CVVHDF clearance rates were 0.6 +/- 0.5 and 3.3 +/- 0.9 liters/h, respectively. In the initial 24 h, doses as low as 0.75 g every 8 h enabled cumulative fractional response of >= 85% for empirical coverage against Pseudomonas aeruginosa, considering a 40% fT (>MIC) (percentage of time the free drug concentration was above the MIC) target. For 100% fT (>MIC), doses of at least 1.5 g every 8 h were required. The median (interquartile range) steady-state trough ceftolozane concentrations for simulated regimens of 1.5 g and 3.0 g every 8 h were 28 (21 to 42) and 56 (42 to 84) mg/liter, respectively. The corresponding tazobactam concentrations were 6.1 (5.5 to 6.7) and 12.1 (11.0 to 13.4) mg/liter, respectively. We suggest a front-loaded regimen with a single 3.0-g loading dose followed by 0.75 g every 8 h for critically ill patients undergoing CVVHDF with study blood and dialysate flow rates.
引用
收藏
页数:11
相关论文